Skip to Content
Find More Like This
Return to Search

CRLF-2 BINDING PEPTIDES, PROTOCELLS AND VIRAL-LIKE PARTICLES USEFUL IN THE TREATMENT OF CANCER, INCLUDING ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

United States Patent Application

20150010475
A1
View the Complete Application at the US Patent & Trademark Office
The present invention relates to the use of which are attached or anchored phospholipid biolayers further modified by CRLF-2 and CD 19 binding peptides which may be used for delivering pharmaceutical cargos, to cells expressing CRLF-2 and CD 19, thereby treating cancer, in particular, acute lymphoblastic leukemia (ALL), including (B-precursor acute lymphoblastic leukemia (B-ALL). Novel CRLF-2 binding peptides and CLRF-2 and CD19-binding viral-like particles (VLPs) useful in the treatment of cancer, including ALL are also provided.
Brinker, C. Jeffrey (Albuquerque, NM), Peabody, David S. (Albuquerque, NM), Wharton, Walker Kip (Corrales, NM), Chackerian, Bryce (Albuquerque, NM), Ashley, Carlee Erin (Albuquerque, NM), Willman, Cheryl L. (Albuquerque, NM), Carnes, Eric C. (Albuquerque, NM), Epler, Katherine (Albuquerque, NM), Castillo, Robert Eric (Albuquerque, NM)
; STC.UNM (Albuquerque MX), SANDA CORPORATION (ALBUQUERQUE MX)
14/ 369,741
December 31, 2012
GOVERNMENT SUPPORT [0002] This invention was made with government support under the NIH/Roadmap for Medical Research under grant PHS 2 PN2 EY016570B; NCI Cancer Nanotechnology Platform Partnership grant 1U01CA151792-01; the Air Force Office of Scientific Research grant 9550-10-1-0054; the U.S. Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering; the Sandia National Laboratories' Laboratory Directed Research and Development (LDRD) program; the President Harry S. Truman Fellowship in National Security Science and Engineering at Sandia National Laboratories (C.E.A.). Accordingly, the United States has certain rights in the invention.